lipid.site

Topics

Lipfendra (enlicitide) experiences

Lipfendra is the first PCSK9 inhibitor taken as a daily pill, approved in 2026. Early experiences from people taking it.

Shared experiences, not medical advice. For decisions about your treatment, talk to your clinician.

Community snapshot

Not enough shared yet (N = 0).

Numbers appear once enough people have shared, so nobody can be singled out. The 1 case written by lipid.site is never counted.

Related exhibitHow each medicine worksStart →
People like me
  • Age 50-59

    Enlicitide (Lipfendra)

    Well tolerated & effective · USD 330/mo · N/A-paid cash

    Has to be taken on an empty stomach, so I take it first thing and wait before coffee.

    Read story

Common questions

Send us a question

Related medicines

Enlicitide (Lipfendra)

Other topics

Statins and muscle painRepatha without insuranceEzetimibe (Zetia) experiencesLerochol (lerodalcibep) experiences